Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl
Visit https://bibliotekanauki.pl
Journal
Article title
Content
Full texts:
Title variants
Languages of publication
Abstracts
Introduction: Acquired hemophilia A (AHA) is an extremely rare, life-threatening bleeding disorder caused by spontaneous development of autoantibodies against clotting factor VIII. Invasive treatments in AHA patients with persistent inhibitor refractory to eradication therapy are highly life-threatening due to the risk of uncontrolled bleeding which responds poorly to surgical methods of hemostasis and bypassing agents.
Case report: This paper discusses the case of a 71-year-old patient with idiopathic AHA and persistent high-titer inhibitor (104 BU) refractory to immunosuppressive treatment and immune tolerance induction therapy. The patient was admitted due to acute bleeding from a gastric ulcer, complicated with a laceration in the mucosa of the gastroesophageal junction (Mallory-Weiss syndrome). The patient underwent repeated endoscopic hemostasis procedures – injection therapy and argon plasma coagulation, which stopped the bleeding. The bypassing agent used was a recombinant activated clotting factor VIII (rFVIIa) at a mean dose of 91.26 µg/kg (up to a total of 134 doses administered over 14 days) and a total dose of 855.52 mg. In conclusion, gastric ulcer bleeding in an AHA patient with persistent inhibitor can be effectively treated with endoscopic methods of hemostasis and appropriate doses of rFVIIa.
Case report: This paper discusses the case of a 71-year-old patient with idiopathic AHA and persistent high-titer inhibitor (104 BU) refractory to immunosuppressive treatment and immune tolerance induction therapy. The patient was admitted due to acute bleeding from a gastric ulcer, complicated with a laceration in the mucosa of the gastroesophageal junction (Mallory-Weiss syndrome). The patient underwent repeated endoscopic hemostasis procedures – injection therapy and argon plasma coagulation, which stopped the bleeding. The bypassing agent used was a recombinant activated clotting factor VIII (rFVIIa) at a mean dose of 91.26 µg/kg (up to a total of 134 doses administered over 14 days) and a total dose of 855.52 mg. In conclusion, gastric ulcer bleeding in an AHA patient with persistent inhibitor can be effectively treated with endoscopic methods of hemostasis and appropriate doses of rFVIIa.
Publisher
Journal
Year
Volume
Issue
Pages
77-80
Physical description
Dates
published
2022
Contributors
author
author
author
author
References
Document Type
Publication order reference
Identifiers
Biblioteka Nauki
58512441
YADDA identifier
bwmeta1.element.ojs-doi-10_5604_01_3001_0014_8451
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.